Sogen Data · Datasets · 数据专题
头颈癌复发轴数据集锦
单细胞 · 空转 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源单细胞
Human · Single-cell
-
01 GSE234933 对头颈癌复发的单细胞基因表达进行分析,采集来自不同解剖部位(口腔、喉/下咽部、口咽部、鼻咽部)的肿瘤组织样本,包含24例原发肿瘤、16例局部复发和12例远处转移样本,其中15例为HPV阳性。样本未进行特定细胞类型富集,以全面代表所有细胞类型。检测方式为单细胞RNA测序,采用CellRanger(版本3.1.0)进行对齐和定量,使用Seurat(版本6)进行质量控制和细胞过滤,依据总读数、表达基因数、线粒体基因比例及标记基因识别双细胞和中性粒细胞。通过UMAP坐标可视化和手动检查进行细胞注释,部分亚群使用projecTILs方法进行亚群分析,未明确分组处理条件。
设计对头颈癌复发的单细胞基因表达进行分析,采集来自不同解剖部位(口腔、喉/下咽部、口咽部、鼻咽部)的肿瘤组织样本,包含24例原发肿瘤、16例局部复发和12例远处转移样本,其中15例为HPV阳性。样本未进行特定细胞类型富集,以全面代表所有细胞类型。检测方式为单细胞RNA测序,采用CellRanger(版本3.1.0)进行对齐和定量,使用Seurat(版本6)进行质量控制和细胞过滤,依据总读数、表达基因数、线粒体基因比例及标记基因识别双细胞和中性粒细胞。通过UMAP坐标可视化和手动检查进行细胞注释,部分亚群使用projecTILs方法进行亚群分析,未明确分组处理条件。
摘要This scRNA dataset was aimed to provide comprehensive profiling of head-and-neck tumor tissues, in order to explore and elucidate patterns of molecular and cellular interactions between the tumor cells and their patient-specific microenvironments. No specific enrichment of a particular cell types were performed to allow comprehensive representation of all cell types. To allow between-patient comparisons, relatively large number of samples from patients with a wide range of patients characteristics and tissue source (primary, recurrence and metastasis) were chosen. The dataset was intended for multiple investigations on specific pathways and cell types of tumor microenvironments.
人源空转
Human · Spatial
-
01 GSE300147 对十例头颈鳞状细胞癌(HNSCC)肿瘤组织进行Xenium V1空间转录组分析,其中五例为HPV阳性。七例HNSCC肿瘤组织在不同天数进行技术重复,分别制备10 µm切片并存储于-80ºC。研究对象包含复发性肿瘤(recurrence: Recurrent)与原发性肿瘤(recurrence: Primary),检测总RNA,分析单细胞分辨率下的转录组特征,比较复发与原发肿瘤的细胞空间分布差异。
设计对十例头颈鳞状细胞癌(HNSCC)肿瘤组织进行Xenium V1空间转录组分析,其中五例为HPV阳性。七例HNSCC肿瘤组织在不同天数进行技术重复,分别制备10 µm切片并存储于-80ºC。研究对象包含复发性肿瘤(recurrence: Recurrent)与原发性肿瘤(recurrence: Primary),检测总RNA,分析单细胞分辨率下的转录组特征,比较复发与原发肿瘤的细胞空间分布差异。
摘要Recent work has shown that the spatial organization of immune responses is a critical determinant of anti-tumor immunity. Here, we profiled ten head and neck squamous cell carcinoma (HNSCC) patient tumors and one ameloblastoma tumor using Xenium V1 spatial transcriptomics. The 10X genomics human multi-tissue and cancer gene expression panel targeting 377 genes was used in combination with 100 custom Xenium probes targeting patient-specific CDR3 regions of T cell receptors (TCRs) in T cells, additoinal T cell specific genes, HPV oncoprotein genes, and tumor genes of interest. This enabled the detection of 477 transcripts within each tumor sample at a single-cell resolution. For seven of the ten HNSCC samples, different tissue sections run on different days were analyzed as technical replicates. Together, these findings introduce a scalable platform for spatial clonal T cell analysis and provide new insight into the spatial relationship of cells within the HNSCC tumor microenvironment.
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE108712 对62例口腔鳞状细胞癌(OSCC)患者的组织样本进行基因表达分析,采集手术切缘组织进行RNA提取并采用NanoString nCounterTM技术检测4个基因(MMP1、COL4A1、P4HA2和THBS2)的表达水平,比较不同患者切缘组织与肿瘤组织的基因表达差异。
设计对62例口腔鳞状细胞癌(OSCC)患者的组织样本进行基因表达分析,采集手术切缘组织进行RNA提取并采用NanoString nCounterTM技术检测4个基因(MMP1、COL4A1、P4HA2和THBS2)的表达水平,比较不同患者切缘组织与肿瘤组织的基因表达差异。
摘要The aim of this study is to provide an extended, retrospective validation of a previously described 4-gene signature (MMP1, COL4A1, P4HA2, and THBS2) predictive of oral carcinoma recurrence. We assessed an independent cohort including 245 histologically normal surgical margins from 62 patients with OSCC. Gene expression was determined using a color-coded probe assay for quantitative gene expression analysis. All margins and tumor blocks were cut (4-5µm tick) and stained with Hematoxylin-Eosin and tissues were subjected to needle microdissection using the stereo microscope Leica EZ4 (Leica Microsystems, Wetzlar, Germany) before RNA extraction, in order to isolate pure tumor or normal cell populations. RNA from FFPE samples was isolated using the RecoverAll Total Nucleic Acid Isolation kit (Ambion/Life Technologies, Carlsbad, CA, USA), following our previously reported protocol with modifications to improve RNA yield [PMID:23835716]. RNA was stored at -80ºC until RNA extraction and gene expression validation. In addition, tumor tissues from the same patients were collected for further analysis (not in scope of the presented study). Probes were designed for the 4-gene signature (MMP1, COL4A1, P4HA2 and THBS2) and contained one capture probe linked to biotin and one reporter probe attached to a color-coded molecular tag for each gene sequence, according to the nCounterTM code-set design. RNA samples were randomized using a numerical ID and were then subjected to NanoString nCounterTM analysis by the Princess Margaret Genomics Centre (https://www.pmgenomics.ca), Toronto, ON, Canada. Patient samples were analyzed in two batches consisting of 125 and 152 margins tissue samples. The detailed protocol for mRNA transcript quantification analysis, including sample preparation, hybridization, detection and scanning followed the manufacturer’s recommendations and was described in [PMID: 21549012]. We used 400 ng of total RNA isolated from FFPE tissues for detection of probe signals. Raw data were analyzed using the nCounterTM digital analyzer software (http://www.nanostring.com/support/ncounter/) and gene expression levels were subjected to further bioinformatic and statistical analyses.
-
02 GSE270047 对复发/转移性头颈癌(R/M HNSCC)患者肿瘤组织的总 RNA 进行 RNA 测序,根据 OncoPrism 分数将样本分为高、中、低三组,比较各组基因表达差异。实验采用技术重复策略,通过改变操作者、试剂批次、制备日期和测序仪验证中间精密度。
设计对复发/转移性头颈癌(R/M HNSCC)患者肿瘤组织的总 RNA 进行 RNA 测序,根据 OncoPrism 分数将样本分为高、中、低三组,比较各组基因表达差异。实验采用技术重复策略,通过改变操作者、试剂批次、制备日期和测序仪验证中间精密度。
摘要While immune checkpoint inhibitor (ICI) therapies can significantly improve outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC), only about 15–20% benefit from such treatments. Clinical tests that guide the use of ICIs are therefore critically needed. OncoPrism-HNSCC was developed to address this need. The assay combines next generation RNA sequencing-based immunomodulatory gene expression signatures with machine learning algorithms to generate an OncoPrism Score that classifies patients as having low, medium, or high likelihood of disease control in response to ICI treatment. Also, OncoPrism-HNSCC leverages the same FFPE patient tumor RNA used for ICI response prediction to identify rare cases where oncogenic rearrangements in NTRK1/2/3 or ALK genes, which may indicate the use of potentially highly effective targeted therapies. The clinical performance of OncoPrism-HNSCC has been validated. Here, we report its analytical performance in the presence of potentially confounding sources of variation.
-
03 GSE67614 对高风险头颈鳞状细胞癌患者接受术后放疗后的肿瘤组织进行基因表达分析,研究对象为术后放疗的头颈鳞状细胞癌患者,样本为肿瘤组织,未提及分组或处理条件,仅采集肿瘤组织进行表达检测。
设计对高风险头颈鳞状细胞癌患者接受术后放疗后的肿瘤组织进行基因表达分析,研究对象为术后放疗的头颈鳞状细胞癌患者,样本为肿瘤组织,未提及分组或处理条件,仅采集肿瘤组织进行表达检测。
摘要Post-operative radiation therapy (PORT) is the standard treatment for patients with head and neck squamous cell carcinoma (HNSCC) having adverse pathological features. Despite PORT, many patients develop relapse causing morbidity and mortality. These specimens are from a high-risk cohort of such patients treated by PORT and are being used to develop gene signatures for therapeutic response.
-
04 GSE31056 研究对象为头颈癌复发的组织样本,包括正常手术切缘、口腔癌及相邻正常组织。从24名患者中收集了96个样本,其中23个为肿瘤样本,73个为切缘样本。通过分析这些样本的基因表达,构建了一个风险模型,用于预测口腔癌在组织学改变前的复发可能性。该模型基于五个已发表的微阵列数据集(GEO编号GDS2520、GDS1584、GSE6791、GSE9844、GSE10121)和当前训练集,识别出在口腔鳞状细胞癌中高表达但在健康口腔组织中未表达的基因。风险特征在30名独立患者提供的136个样本中通过定量实时逆转录PCR进行验证。
设计研究对象为头颈癌复发的组织样本,包括正常手术切缘、口腔癌及相邻正常组织。从24名患者中收集了96个样本,其中23个为肿瘤样本,73个为切缘样本。通过分析这些样本的基因表达,构建了一个风险模型,用于预测口腔癌在组织学改变前的复发可能性。该模型基于五个已发表的微阵列数据集(GEO编号GDS2520、GDS1584、GSE6791、GSE9844、GSE10121)和当前训练集,识别出在口腔鳞状细胞癌中高表达但在健康口腔组织中未表达的基因。风险特征在30名独立患者提供的136个样本中通过定量实时逆转录PCR进行验证。
摘要Samples were prospectively collected from patients with histologically normal surgical resection margins. 96 tissue samples (histologically normal margins, oral carcinoma and adjacent normal tissues) from 24 patients comprised the training set. Our study design was guided by the hypothesis that the expression of genes present in oral squamous cell carcinoma (OSCC) but not in healthy oral tissues would be indicative of recurrence in advance of histological alteration. We used meta-analysis of five published microarray data sets (GEO accession GDS2520, Kuriakose et al. 2004; GDS1584, Toruner et al. 2004; GSE6791, Pyeon et al. 2007; GSE9844, Ye et al. 2008; and GSE10121, Sticht et al. 2008), in conjunction with the current training set, to identify genes reliably over-expressed in OSCC. This reduced gene set was used to train a risk model to predict recurrence based on over-expression of a subset of these genes in histologically normal surgical resection margins. Validation of the risk signature was performed using quantitative real-time reverse-transcription PCR in an independent set of 136 samples from an independent cohort of 30 patients.
-
05 GSE212549 对复发/转移性头颈鳞状细胞癌(RM HNSCC)患者进行表达谱分析,这些患者接受纳武利尤单抗(nivolumab)治疗,样本为FFPE组织,共80个样本。
设计对复发/转移性头颈鳞状细胞癌(RM HNSCC)患者进行表达谱分析,这些患者接受纳武利尤单抗(nivolumab)治疗,样本为FFPE组织,共80个样本。
摘要In recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC) not amenable to salvage surgery or radiation, the overall survival remains unsatisfactory, and the patients often experience a huge burden of symptoms requiring treatments that could achieve objective response on the disease itself. Recently, treatment with immune checkpoint inhibitors (ICI) has shown survival benefit in randomized clinical trials both in the setting of platinum pre-treated patients and in patients at their first line of treatment, with the expression of PDL1 on the tumor. Despite the introduction of ICI, only a small subset of RM HNSCC patients achieves long-term survivorship. We aim at identifying predictors of outcome and evaluating a gene expression signature (Cl6-immunereactive) in patients treated with ICI therapy. Our data highlight the presence of biological underlying differences able to predict outcome following treatment with ICI for platinum-refractory RM-HNSCC.
-
06 GSE148944 研究对象为67例头颈癌复发的bulk RNA样本,包含原发性口腔舌鳞状细胞癌、伴有淋巴结转移的病例及复发转移性病例,同时纳入10例非癌舌组织样本。采用免疫组化和Nanostring PanCancer免疫分析面板检测CD4、CD8、FOXP3、PD-L1及PD-1等靶点表达,分析不同疾病阶段的免疫特征差异,比较复发病例与非复发病例的PD-L1表达水平及免疫基因活性变化。
设计研究对象为67例头颈癌复发的bulk RNA样本,包含原发性口腔舌鳞状细胞癌、伴有淋巴结转移的病例及复发转移性病例,同时纳入10例非癌舌组织样本。采用免疫组化和Nanostring PanCancer免疫分析面板检测CD4、CD8、FOXP3、PD-L1及PD-1等靶点表达,分析不同疾病阶段的免疫特征差异,比较复发病例与非复发病例的PD-L1表达水平及免疫基因活性变化。
摘要We investigated whether a unique immune response was instigated with the development of oral tongue squamous cell carcinomas (OTSCC), with/without nodal involvement, with/without recurrent metastatic disease, or within tumor involved nodes. 110 FFPE samples were collected from a retrospective cohort of 67 OTSCC patients and 10 non-cancerous tongue samples. Targets including CD4, CD8, FOXP3, PD-L1 and PD-1 were analyzed by immunohistochemistry. The Nanostring PanCancer Immune Profiling Panel was used for gene expression profiling. Data were externally validated in the TCGA head and neck (HNSCC), melanoma and lung squamous cell carcinoma (LSCC) cohorts. A 24-immune gene signature was identified that discriminated more aggressive OTSCC cases, and although not prognostic in HNSCC was associated with survival in other TCGA cohorts (improved survival for melanoma, p<0.001 and worse survival for LSCC, p=0.038). OTSCC exhibited concordant gene and IHC features characterized by a TH-2 biased, pro-inflammatory profile with upregulated B cell and neutrophil gene activity and increased CD4, FOXP3 and PD-L1 expression (p<0.001 for all by IHC). Compared to less advanced disease, nodal involvement and recurrent OTSCC did not induce a different immune response although recurrent disease was characterized by significantly higher PD-L1 expression (p=0.004 by SP263, p=0.013 by 22C3, p=0.004 for gene expression). Identification of a gene signature associated with different prognostic effects in other cancers highlights common pathways of immune dysregulation that are impacted by the tumor origin. The significant immunosuppressive signaling in OTSCC indicates primary failure of immune system to control carcinogenesis emphasizing the need for early, combination therapeutic approaches.
-
07 GSE85446 对66例HPV阴性口腔鳞状细胞癌原发肿瘤进行基因表达分析,并与GSE30788中84例HPV阴性口腔鳞状细胞癌原发肿瘤的基因表达数据进行整合分析。
设计对66例HPV阴性口腔鳞状细胞癌原发肿瘤进行基因表达分析,并与GSE30788中84例HPV阴性口腔鳞状细胞癌原发肿瘤的基因表达数据进行整合分析。
摘要Gene expression profiling of 66 HPV-negative OSCC primary tumor was performed to identify gene expression that is related to lymph node metastasis and poor prognosis. These gene expression profiles were combined in silico with gene expression profiles of 84 OSCC primary tumors retrieved from GSE30788.
-
08 GSE25727 对早期喉癌患者进行基因表达模型的识别与验证,采用全基因组 DASL 数组表达分析技术,对 56 例福尔马林固定石蜡包埋的肿瘤样本进行检测,样本分为训练集和验证集,通过监督主成分生存分析在训练集中识别预测复发风险的基因表达特征,并在验证集中进行验证。
设计对早期喉癌患者进行基因表达模型的识别与验证,采用全基因组 DASL 数组表达分析技术,对 56 例福尔马林固定石蜡包埋的肿瘤样本进行检测,样本分为训练集和验证集,通过监督主成分生存分析在训练集中识别预测复发风险的基因表达特征,并在验证集中进行验证。
摘要Background Despite improvement in diagnostic and therapeutic techniques, a significant percentage of patients with early stage laryngeal cancer still recur after treatment. Gene expression models prognostic of recurrence risk could suggest which patients with early stage laryngeal cancer would be more appropriate for testing adjuvant strategies. Patients and Methods Expression profiling using whole genome DASL arrays was performed on 56 formalin-fixed paraffin-embedded tumor samples of patients with early stage laryngeal cancer, treated with surgery or radiation therapy. We split the samples into a training set and a validation set. Using the supervised principal components survival analysis in the first cohort, we identified multiple gene expression profiles that predict the risk of recurrence. These profiles were then validated in the second independent cohort. Results Gene models comprising different number of genes (40-100) identified a subgroup of patients who were at high risk of recurrence. Of these, the best prognostic model distinguished between a high- and a low-risk group (median DFS: 92 and 123 months, log rank p<0.005, permutation p<0.05), Hazard Ratio (HR): 8.51 (95% CI, 1.01 to 71.77; p<0.05). These models performed similarly in the independent cohort of our study (median DFS: 38 vs 161 months, log rank p=0.018), HR=5.19 (95% CI, 1.14 to 23.57; p<0.05). Conclusions We have identified gene expression prognostic models which can refine the estimation of a patient’s risk of recurrence. These findings, if further validated, should aid in patient stratification for testing adjuvant treatment strategies.
-
09 GSE10288 对13例喉癌组织和10例非肿瘤喉组织样本进行基因表达谱分析,使用定制cDNA微阵列检测332个探针对应的285个基因表达差异,比较肿瘤与非肿瘤组织的基因表达特征。
设计对13例喉癌组织和10例非肿瘤喉组织样本进行基因表达谱分析,使用定制cDNA微阵列检测332个探针对应的285个基因表达差异,比较肿瘤与非肿瘤组织的基因表达特征。
摘要Laryngeal squamous cell carcinoma is a very common in head and neck cancer, accounting for 25% of all cases, with high mortality rates and poor prognosis. In this study, we compared expression profiles of clinical samples from15 larynx tumors and 10 non-neoplastic larynx tissue using a custom-built cDNA microarray containing 332 probes for 285 genes previously identified as up- or down-regulated in head and neck tumors by the Head and Neck Annotation Consortium (Reis et al., Cancer Res 65:1693-99, 2005). Thirty-five genes showed statistically significant differences (SNR ≥|1.0|,p-value ≤ 0.001) in expression between tumor and non-tumor larynx tissue samples. Functional annotation indicated that these genes are involved in cellular processes relevant to the cancer phenotype, such as apoptosis, cell cycle, DNA repair, proteolysis, protease inhibition, signal transduction, and transcription regulation. Six of the identified transcripts map to intronic regions of protein-coding genes and may comprise unannotated exons or yet uncharacterized long ncRNAs with a regulatory role in the gene expression program of larynx tissue. Differential expression of 10 of these genes (ADCY6, AES, AL2SCR3, CRR9, CSTB, DUSP1, MAP3K5, PLAT, UBL1 and ZNF706) was independently confirmed by quantitative real-time RT-PCR. Among these, the CSTB gene product has cysteine protease inhibitor activity that has been associated to an antimetastatic function. Interestingly, CSTB showed low expression in all tumor samples analyzed (p-value < 0.0001). The set of genes identified here contribute to a better understanding of the molecular basis of larynx cancer, and at the same time provide novel candidate markers for improving diagnosis, prognosis and treatment of this carcinoma. Keywords: Gene expression profiling of larynx tumors and non-neoplastic adjacent tissue
-
10 GSE199029 对头颈癌复发的bulk RNA样本进行研究,分析烟草使用与不良肿瘤学结局相关的基因组和免疫特征。采集了44例HPV阳性头颈癌样本,通过全外显子组测序和靶向mRNA杂交技术检测突变差异及肿瘤免疫微环境特征,比较烟草使用与非使用组的转录特征差异。
设计对头颈癌复发的bulk RNA样本进行研究,分析烟草使用与不良肿瘤学结局相关的基因组和免疫特征。采集了44例HPV阳性头颈癌样本,通过全外显子组测序和靶向mRNA杂交技术检测突变差异及肿瘤免疫微环境特征,比较烟草使用与非使用组的转录特征差异。
摘要Tobacco use is an independent adverse prognostic feature in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Despite this, the biologic features associated with tobacco use have not been systematically investigated in this population. We sought to characterize the genomic and immunologic features of HPV(+) OPSCC associated with tobacco use and adverse oncologic outcomes. Whole exome sequencing of 47 primary HPV(+) OPSCC tumors was performed to investigate mutational differences associated with tobacco exposure. To characterize the tumor immune microenvironment (TIME), targeted mRNA hybridization was performed. Low expression of transcripts in a T cell-inflamed gene expression profile (TGEP) was associated with tobacco use at the time of diagnosis and lower overall and disease-free survival. Tobacco use was associated with an increased proportion of T>C substitutions and a lower proportion of mutational signatures typically observed in HPV(+) OPSCC tumors, but was not associated with increases in mutational burden or the rate of recurrent oncogenic mutations. Our work suggests that rather than increased mutational burden, tobacco’s primary and clinically relevant association in HPV(+) OPSCC is immunosuppression of the tumor immune microenvironment.
-
11 GSE65021 对接受铂类和西妥昔单抗一线化疗的头颈癌复发或转移患者进行基因表达微阵列分析,将患者按无进展生存期(PFS)分为长PFS组(PFS>12个月)和短PFS组(PFS<5.6个月),比较两组间肿瘤组织的分子特征差异。研究对象为复发或转移患者,样本为肿瘤组织,检测方式采用全基因组DASL assay结合HumanHT-12_v4 BeadArray芯片,分组依据为PFS时长。
设计对接受铂类和西妥昔单抗一线化疗的头颈癌复发或转移患者进行基因表达微阵列分析,将患者按无进展生存期(PFS)分为长PFS组(PFS>12个月)和短PFS组(PFS<5.6个月),比较两组间肿瘤组织的分子特征差异。研究对象为复发或转移患者,样本为肿瘤组织,检测方式采用全基因组DASL assay结合HumanHT-12_v4 BeadArray芯片,分组依据为PFS时长。
摘要First line chemotherapy with platinum and cetuximab is usually offered to RM-HNSCC pts. In the Extreme trial a median progression free survival (PFS) time of 5.6 months was reported. However, a small fraction of pts achieves a prolonged PFS (> than 12 months). Till now, no recognized predictive biological factor has been identified.
-
12 GSE304200 对头颈鳞状细胞癌肿瘤样本进行bulk RNA测序,比较初次未治疗肿瘤与放疗后复发肿瘤中癌症睾丸抗原的表达差异。样本根据患者是否为初次诊断或放疗后活检分为两类,分别采集肿瘤组织进行RNA-Seq分析,检测polyA RNA并量化基因表达。
设计对头颈鳞状细胞癌肿瘤样本进行bulk RNA测序,比较初次未治疗肿瘤与放疗后复发肿瘤中癌症睾丸抗原的表达差异。样本根据患者是否为初次诊断或放疗后活检分为两类,分别采集肿瘤组织进行RNA-Seq分析,检测polyA RNA并量化基因表达。
摘要We performed bulk RNA sequencing on head and neck squamous cell carcinoma (HNSCC) tumors to identify, characterize, and select specifc cancer-testis antigens (CTAs) as potential precision immuno-oncologic targets. Specifically, we compared CTA expression between previously untreated (de novo) tumors and radiation-recurrent tumors to assess expression patterns in different clinical settings.
-
13 GSE293443 对32例人类头颈癌患者FFPE组织样本进行RNA测序,包含11例复发肿瘤标本与21例非复发肿瘤标本,比较两组基因表达差异。采用Illumina NovaSeq 6000平台进行配对末端测序(2 × 101 bp),通过cDNA文库策略提取总RNA,检测对象为FFPE组织切片样本。
设计对32例人类头颈癌患者FFPE组织样本进行RNA测序,包含11例复发肿瘤标本与21例非复发肿瘤标本,比较两组基因表达差异。采用Illumina NovaSeq 6000平台进行配对末端测序(2 × 101 bp),通过cDNA文库策略提取总RNA,检测对象为FFPE组织切片样本。
摘要RNA sequencing of 32 FFPE tissue samples, including 11 recurrent and 21 non-recurrent tumor specimens demonstrated higher KRT1 gene expression in the recurrence group than in non-recurrent cases. Patients with KRT1-positive immunostaining exhibited trends of worse overall survival (OS) and recurrence-free survival (RFS). In vitro studies showed that KRT1 knockdown suppressed tumor cell invasion, cell migration, and expression of epithelial-mesenchymal transition (EMT)-related genes in human head and neck squamous cell carcinoma (HNSCC) cell lines. Additionally, KRT1 knockdown enhanced tumor cell apoptosis and exhibited synergistic effects with conventional radiation and chemotherapy treatments. KRT1 may serve as a biomarker for predicting advanced laryngeal cancer recurrence and assist with selecting patients to receive concurrent chemoradiotherapy (CCRT).
-
14 GSE102995 对头颈鳞状细胞癌患者FFPE肿瘤标本进行基因表达分析,其中20例来自原发肿瘤、5例来自复发/转移肿瘤,样本按肿瘤来源分组。采用DASL微阵列(Illumina)检测总RNA表达特征,比较原发与复发/转移肿瘤的基因表达差异,识别与长进展无病生存期(PFS)相关的分子亚型及短PFS病例的RAS信号通路激活状态。
设计对头颈鳞状细胞癌患者FFPE肿瘤标本进行基因表达分析,其中20例来自原发肿瘤、5例来自复发/转移肿瘤,样本按肿瘤来源分组。采用DASL微阵列(Illumina)检测总RNA表达特征,比较原发与复发/转移肿瘤的基因表达差异,识别与长进展无病生存期(PFS)相关的分子亚型及短PFS病例的RAS信号通路激活状态。
摘要Platinum-based chemotherapy plus cetuximab, an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody (Mab), is usually offered to recurrent/metastatic (R/M) head-neck squamous cell carcinoma (HNSCC) patients, with only a small portion experiencing durable responses. The anti-EGFR-Mab panitumumab, was used as single agent in platinum pre-treated R/M-HNSCC patients in a phase II trial (PANI01). By analyzing gene expression profiles of a selected retrospective series of HNSCC patients treated with cetuximab, an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody (MAb), associated to chemotherapy, we were able to propose that long progression-free survival (PFS) cases consistently belong to defined molecular subtypes, such as Cluster3-hypoxia and Basal subtypes, respectively defined by De Cecco et al [DeCecco; Oncotarget, 2015] and Keck et al [Keck; CCR,2015], while short-PFS cases are characterized by an over-activation of RAS signaling
-
15 GSE179730 分析12名头颈癌患者的治疗前、治疗后及复发阶段的肿瘤和血液样本,通过RNA-Seq检测基因表达,比较不同时间点的肿瘤和血液样本中FLT4突变、PTEN信号富集、肿瘤突变负担及CDKN2A/YAP1/JAK2突变与治疗反应及复发的关系。
设计分析12名头颈癌患者的治疗前、治疗后及复发阶段的肿瘤和血液样本,通过RNA-Seq检测基因表达,比较不同时间点的肿瘤和血液样本中FLT4突变、PTEN信号富集、肿瘤突变负担及CDKN2A/YAP1/JAK2突变与治疗反应及复发的关系。
摘要Neoadjuvant PD-1 blockade may be efficacious in patients with high-risk, resectable oral-cavity, head-and-neck cancer. To explore correlates of response patterns to neoadjuvant nivolumab treatment and post-surgical recurrences, we analyzed longitudinal tumor and blood samples in a cohort of 12 patients displaying 33% responsiveness. Pretreatment tumor-based detection of FLT4 mutations and PTEN signature enrichment favors response, and high tumor mutational burden improves recurrence-free survival. In contrast, preexisting and/or acquired mutations (in CDKN2A, YAP1, JAK2) correlate with innate resistance and/or tumor recurrence. Immunologically, tumor response after therapy entails T-cell receptor repertoire diversification in peripheral blood and intratumoral expansion of preexisting T-cell clones. A high ratio of regulatory to Th17 T cells in pretreatment blood predicts innate resistance, low cytolytic T-cell signature in pretreatment tumor, and low T-cell receptor repertoire diversity in pretreatment blood. Our study provides a molecular framework to advance neoadjuvant anti-PD-1 therapy for patients with resectable head-and-neck cancer.
-
16 GSE165883 对HPV相关头颈癌原发和复发肿瘤样本进行RNA-Seq测序,比较其转录特征。研究共分析20个样本,包括12对原发与复发肿瘤,其中两对因质量低未纳入下游分析。复发肿瘤分为local、regional和distant类型,但未按复发部位分组比较。
设计对HPV相关头颈癌原发和复发肿瘤样本进行RNA-Seq测序,比较其转录特征。研究共分析20个样本,包括12对原发与复发肿瘤,其中两对因质量低未纳入下游分析。复发肿瘤分为local、regional和distant类型,但未按复发部位分组比较。
摘要Human papillomavirus (HPV) infection drives the development of some head and neck cancer squamous cell carcinomas (HNSC). Although these tumors are sensitive to treatment, ~10% of patients fail therapy. However, the mechanisms that underlie treatment failure remain unclear. Here, we assessed the transcriptional profiles of 10 paired primary and subsequent recurrent HPV-related oropharyngeal squamous cell carcinomas (OPSCCs) using an exome-capture hybrid RNA sequencing assay. Principal componenent analysis using the expression data from the top 500 most variable genes revealed that 29.3% of the variance was aassociated with tumor status (i.e., primary vs recurrent tumor). Four of the primary/recurrent tumor pairs demonstrated greater clustering based on the patient of origin rather than the tumor status (primary vs recurrent). Additionally, two of the recurrences were distant, two were local, and the remaining six were regional. The recurrent tumors did not cluster necessairly based on site of recurrence. Unsupervised heirarchical clustering of the top 500 most variable genes revealed a correlation between recurrent tumors and metabolic gene expression while the primary tumors demonstrated increased expression in several immunologic related genes, mitogenic signaling, and epigenetic signaling genes. Using the PANTHER GO-Slim biological process pathway analysis, we identified enrichment of processes involved in biosynthesis, metabolism including oxidative phosphorylation, and Wnt signaling. Using gene set enrichment analysis, we observed enrichment in oxidative phosphorylation, fatty acid metabolism, and glutathione metabolism as well as MYC, P53-dependent DNA damage repair, and NRF2 pathway gene expression among the recurrent HPV-associated OPSCCs.
-
17 GSE87593 将IV期口腔鳞状细胞癌患者按术后复发状态分为复发组和非复发组,每组4人,分别采集其原发肿瘤组织和区域淋巴结样本(样本类型为FFPE),通过cDNA微阵列分析检测总RNA的基因表达水平,比较两组在肿瘤及淋巴结组织中的差异。
设计将IV期口腔鳞状细胞癌患者按术后复发状态分为复发组和非复发组,每组4人,分别采集其原发肿瘤组织和区域淋巴结样本(样本类型为FFPE),通过cDNA微阵列分析检测总RNA的基因表达水平,比较两组在肿瘤及淋巴结组织中的差异。
摘要To characterize differential gene expression patterns and their actual expression in tissues for recurrent and non-recurrent tumors to identify independent prognostic markers for oral squamous cell carcinoma (OSCC).
-
18 GSE217142 对3例口腔鳞状细胞癌患者在诊断时和复发时的肿瘤组织进行RNA测序,比较同一名患者原发与复发肿瘤样本的基因表达差异。研究对象为人类口腔鳞状细胞癌患者,被测材料为肿瘤组织,检测方式为RNA测序,样本量为6个(3例患者各含原发和复发样本),主要比较同一名患者不同时间点的肿瘤样本。
设计对3例口腔鳞状细胞癌患者在诊断时和复发时的肿瘤组织进行RNA测序,比较同一名患者原发与复发肿瘤样本的基因表达差异。研究对象为人类口腔鳞状细胞癌患者,被测材料为肿瘤组织,检测方式为RNA测序,样本量为6个(3例患者各含原发和复发样本),主要比较同一名患者不同时间点的肿瘤样本。
摘要We report the results of RNAseq analysis using the NovaSeq platform of primary human cancer patient samples at diagnosis and following recurrence.
鼠源bulk 转录组
Mouse · Bulk RNA-seq
-
01 GSE35377 对小鼠口腔原发瘤和复发瘤进行微阵列表达分析,比较两者的基因表达差异。研究包含5个原发瘤样本和5个对应的复发瘤样本,以及用于生成肿瘤的SCC-7细胞系的两个重复样本。
设计对小鼠口腔原发瘤和复发瘤进行微阵列表达分析,比较两者的基因表达差异。研究包含5个原发瘤样本和5个对应的复发瘤样本,以及用于生成肿瘤的SCC-7细胞系的两个重复样本。
摘要We applied global gene expression with samples derived from a recently established mouse model for oral cancer recurrences and identified a list of genes with differential expression between primary and recurrent tumors.

课题合作 · 扫码加微信
bioinformaticsboy